# OnCo record paper-flaura2-long-term-safety-lung-cancer-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-flaura2-long-term-safety-lung-cancer-2026" ;
  schema:name "FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer"@en ;
  schema:description "Side effects of the osimertinib plus chemotherapy combination were most frequent in the first four chemotherapy cycles and fell steadily once patients moved to maintenance and then to osimertinib alone; few had to stop osimertinib because of them."@en ;
  schema:url <https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/> ;
  schema:dateModified "2026-09-21"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/j.lungcan.2026.109588>, <https://pubmed.ncbi.nlm.nih.gov/42728193/>, <https://clinicaltrials.gov/study/NCT04035486> ;
  schema:sameAs <https://doi.org/10.1016/j.lungcan.2026.109588> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Planchard D, Jänne PA, Yang JC, et al." ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/egfr-mutant-nsclc/> ;
  onco:targets <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:terms <https://onco.cc/terms/first-line/> ;
  onco:trials <https://onco.cc/trials/flaura2/> ;
  onco:people <https://onco.cc/people/david-planchard/>, <https://onco.cc/people/pasi-janne/> ;
  onco:journals <https://onco.cc/journals/lung-cancer-journal/> .